UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): March 13, 2023 |
ACASTI PHARMA INC.
(Exact name of Registrant as Specified in Its Charter)
| | | | |
Quebec | 001-35776 | 98-1359336 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer
Identification No.) |
| | | | |
3009, boul. de la Concorde East Suite 102 | |
Laval, Quebec | | H7E 2B5 |
(Address of Principal Executive Offices) | | (Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: 450 686-4555 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class
| | Trading
Symbol(s) | |
Name of each exchange on which registered
|
Common Shares, no par value per share | | ACST | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On March 13, 2023, Acasti Pharma Inc. (the "Company") issued a press release announcing that it has applied and received approval for a voluntary delisting of its common shares from the TSX Venture Exchange ("TSXV") and also confiming that neither the Company nor any of its subsidiaries have any exposure to Silicon Valley Bank or Silvergate Bank. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing or document.
Item 8.01 Other Events.
On March 13, 2023, the Company announced that it has applied and received approval for a voluntary delisting of its common shares from the TSXV. The delisting from the TSXV will not affect the Company's listing on the Nasdaq Capital Market (the "NASDAQ"). The common shares will continue to trade on the NASDAQ under the symbol "ACST". It is anticipated that, effective as at the close of trading on March 27, 2023, the Company's common shares will no longer be listed and posted for trading on the TSXV.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| | | Acasti Pharma Inc. |
| | | |
Date: | March 13, 2023 | By: | /s/ Jan D'Alvise |
| | | Jan D'Alvise, Chief Executive Officer |
